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A B S T R A C T
Based on the ancient role of oxytocin and its homologues as amplifiers of reproduction we argue for an evolutionary coupling of oxytocin to signaling pathway which
support restorative mechanisms of cells and tissue. In particular, the survival and function of different categories of stem cells and primordial cells are enhanced by
mitogen-activated protein kinase (MAPK) pathways. Furthermore, oxytocin stimulates the AMP-activated protein kinase pathway (AMPK) in numerous of cell types
which promotes the maintenance of different cell structures. This involves autophagic processes and, in particular, may support the renewal of mitochondria.
Mitochondrial fitness may protect against oxidative and inflammatory stress - a well-documented effect of oxytocin. The combined specific trophic and protective
effects oxytocin may delay several degenerative phenomena including sarcopenia, type-2 diabetes and atherosclerosis. These effects may be exerted both on a central
level supporting the function and integrity of the hypothalamus and peripherally acting directly on blood vessels, pancreas, heart, skeletal muscles and adipose tissue
etc. Furthermore, in the capacity of being both a hormone and neuromodulator, oxytocin interacts with numerous of regulatory mechanisms particularly the
autonomic nervous system and HPA-axis which may reduce blood pressure and affect the immune function. The potential of the oxytocin system as a behavioral and
molecular target for the prevention and treatment of cardiovascular disease is discussed. Focus is put on the affiliative and sexual significance and the different
options and limitations associated with a pharmaceutical approach.
MeSH: Aging, Atherosclerosis, Heart, Hypothalamus, Inflammation, Love, Orgasm, Oxytocin.
Background
Members of the oxytocin/vasopressin family have presumably been
around for about 600 million years since homologues of these non-
apeptides can be found in primitive invertebrates as nematodes and
annelids [1]. Similar to what is the case in humans and other mammals,
the peptides are important in primitive organisms for behavior and
muscle contractions involved in reproduction.
The nematode Caenorhabditis Elegans has extensively been applied
to study the connection between reproduction and life span. In this
worm primordial egg cells may produce a compound which compro-
mises the autophagy function. Autophagy is important for cell main-
tenance as it eliminates dysfunctional components such as misfolded
proteins and defective mitochondria. The removal of the germ line cells
therefore expands the lifetime of the animal [2]. The mechanism that
impairs autophagy appears to be intertwined with the mobilization of
fat as energy for the offspring [2]. Such a link between reproduction
and degeneration, possibly leading to death of the progenitor, may be
profitable for primitive organisms with a fast reproduction when the
resources are confined. However, in species which have developed a
strategy to reproduce more than once or where the offspring requires
nursing, measures are needed to counteract the degeneration and death
of the parent. An evolutionary coupling between reproductive signaling
and the protection against decay of the mother therefore appears to be
likely. In general, this would also favor sexually active individuals ra-
ther than individuals not contributing to the progress of the population.
In this context, it would be plausible to suggest an early development of
associations between oxytocin homologues and cell protective path-
ways that may have been preserved in humans.
Hypothesis
Oxytocin has some general antioxidative, anti-inflammatory and
restorative properties which gives this peptide a potential as a remedy
for the protection and treatment of cardiovascular disease. Based on
biological research and epidemiological findings we discuss how to
approach the oxytocin system by pharmaceutical and behavioral ave-
nues.
Oxytocin may protect against oxidative stress and inflammation by
interfering with intracellular energy managing systems
Oxytocin may exert some of its protective effect by the stimulation
of the AMP activated protein kinase (AMPK) pathways. AMPK is
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suggested to be an ancient general sensor of a low energy status of the
cells, as it is activated as a result of low levels of the ATP/AMP ratio. Its
activation normally causes the cell to switch from an anabolic to a
catabolic state by the stimulation of glycolysis and fat oxidation and
inhibition of triglyceride, glycogen, protein syntheses and other ATP
requiring processes. This prevents that an energy deficit builds up in the
cell [3]. In addition to being activated by a declining energy level,
AMPK activity is also enhanced with increasing level of Ca2+ by the
Ca2+/calmodulin-dependent protein kinase (CAMK) pathway. This
may be an important mechanism during muscle contractions [4]. The
contractive effect of oxytocin on smooth muscles is elicited via its G-
protein coupled receptor mediating an increased intracellular con-
centration of Ca2+ [5]. However, in skeletal muscles oxytocin has been
demonstrated to have the potential to enhance the Ca2+ concentration
to a subcontractive level which induces an activation of AMPK [6].
Without yet being confirmed, oxytocin might also activate AMPK in
non-contractive cell types.
A capacity of oxytocin, in this way, to promote a general fuel mo-
bilization at the expense of energy storage in the mother may have
evolved to facilitate the provision of nutrients for the offspring. In ad-
dition to the mild catabolic effect, the activation of AMPK may improve
the efficiency and capacity of respiration by supporting the fitness of
the mitochondria. In this context, AMPK has been demonstrated both to
promote the autophagy of damaged mitochondria and to support the
construction of new [7]. Replacement of defective mitochondria may
also be important to minimize mitochondrial production of Reactive
Oxygen Species (ROS) as demonstrated in yeast [8]. It is well estab-
lished that ROS damage different cell components including DNA, lipid
membranes, proteins and, in particular, the mitochondria and may
accelerate the development of degenerative diseases [9,10]. Apart from
its stimulation of mitochondria renewal, increased AMPK activity may
also lead to the upregulation of UCP2, an uncoupling protein with an
acute regulatory impact on the ROS production of the mitochondria
[11]. Elevated ROS levels are linked to an increased inflammatory ac-
tivity where stimulation of the NF-κB pathway may be an important
factor [12]. In this context, the anti-inflammatory effects of several
different hormones and drugs has been proposed to be mediated by
AMPK indirectly acting on NF-κB [13]. ROS produced by the mi-
tochondria appears to be important for the immune response as de-
monstrated in UCP2 knock-out mice which were more resistant against
infections but more liable to develop atherosclerosis and autoimmune
diseases [14].
In addition to the UCP’s, an uncoupling function of the mitochon-
drial ATP-dependent potassium (mitoKATP) channel has been sug-
gested to play a crucial protective role against reperfusion damages
when oxytocin was administered in an in-situ study with rat hearts [15].
A later study from the same group supported an important role of Nitric
Oxide (NO) in this cardioprotective effect of oxytocin [16]. This is
plausible, as the vasodilatory effect of oxytocin may depend on a NO
release from the endothelium [17].
Mammalian target of rapamycin (mTOR) is another part of the en-
ergy responsive system of the cells. In its active form this serine/
threonine protein kinase stimulates growth including protein and lipid
synthesis whereas it generally inhibits autophagy [18]. mTOR is acti-
vated by growth factors conditioned by some amino acids [18] but is
inhibited by AMPK [19]. A high AMPK activity induced by oxytocin
may in this way increase the level of autophagy. However, the function
of oxytocin as a mild catabolic hormone is emphasized by its potential
to inhibit mTOR independently of AMPK [20].
Several studies applying different models both in mammals and
invertebrates have reported that life and health span can be extended
substantially by inhibition of the mTOR pathway. An improved mi-
tochondrial function with a reduced formation of ROS may be an im-
portant factor in the life extending effect of the TOR-inhibitor rapa-
mycin [21]. In mice where the mTOR gene has been manipulated only
to be expressed at a level of 25% lived on average 22% longer without
any changes in their metabolic profile compared to the wild type mice.
Furthermore, the manipulated mice demonstrated less aggregation of
defective proteins with age which may be interpreted as an improved
autophagy [22]. Some of the beneficial effects of exercise [23] and
caloric restriction [24] has been proposed to involve the same catabolic
pathways.
Thus, the mechanisms of oxytocin to ensure sufficient nutrient
supply by promoting catabolic mechanisms and respiratory efficiency
may at the same time dampen oxidative stress and stimulate the
maintenance systems of the cell. This could be considered to have
evolved as a fortunate byproduct of oxytocin’s engagement in muscle
contractions and the associated Ca2+ mediated pathways. Hence, the
role of Ca2+ as a second messenger beyond what is required for con-
traction can also be applied by oxytocin in noncontractile cells.
Oxytocin promotes cell maintenance systems and restorative processes by
Ca2+-independent pathways
Oxytocin stimulates, by its G-protein coupled receptor, several
signal transduction systems which probably never have been re-
sponsible for muscle contractions. In this context it is important to
mention the Akt and ERK1/2 pathways which promote survival of
stressed cells. ERK signaling is a mediator of oxytocin’s stimulation of
prostaglandin-2 (PGE-2) production [25]. Increased PGE-2 release is
well established as an important mechanism for oxytocin to initiate
myometrial contractions during labor [26]. However, PGE-2 also ap-
pears to have a pivotal role by promoting the survival and proliferative
capacity of different types of stem cells [27]. By supporting stem cell
function oxytocin may have acquired a general capacity to preserve the
integrity of different tissues. This exemplifies that the oxytocin/vaso-
pressin family also has evolved a function as a general strength-en-
hancing and life span extending factor.
In particular, the capacity of mesenchymal stem cells (MSC) and
different progenitor cells to repair various tissue damages appears to be
enhances by oxytocin. Focus has been put on the treatment of myo-
cardial infarctive lesions with MSC. Thus, the proliferation and che-
motaxis of rat bone marrow MSC was increased when incubated with
oxytocin at a concentration of 10-10 M [28] corresponding to about high
physiological blood concentrations. In the same study, MSC also de-
monstrated a greater survival rate during starvation and hypoxia when
treated with oxytocin. However, these effects of oxytocin were ablated
when the cells contemporarily were treated with substances which
blocked the Akt and ERK1/2 pathways. Furthermore, a protective effect
against apoptosis of isolated cardiomyocytes during exposure to hy-
poxia and starvation was observed when the cells were cocultured with
MSC. This impact on MSC on the cardiomyocytes was reinforced when
the MSC have been conditioned by oxytocin. This indicates the presence
of guarding paracrine effects from stem cells which can be enhanced by
oxytocin. Accordingly, the secretion from MSC of a number of cytokines
related to growth, migration and survival was found to be increased
when the cells were treated with oxytocin.
A stimulation of the ERK1/2 pathway also seems crucial when
oxytocin exerts an antisenescent effect on dermal fibroblasts. When
cultured in a medium conditioned by senescent fibroblasts, non-
senescent fibroblasts achieved from young women were found to ac-
quire the senescence-associated secretory phenotype (SASP) char-
acterized by an increased production of proinflammatory cytokines
[29]. This illustrates a capacity of senescent cells to inflict senescence
on neighboring cells by paracrine effects causing them to go into cells
cycle arrest which may compromise tissue repairment. However, when
oxytocin was added to the conditioned media senescence of the fibro-
blasts was delayed and the proliferative capacity of the cells was pro-
tected. Moreover, the beneficial effect of oxytocin was abolished if
ERK1/2 signaling was blocked by a MAPK kinase inhibitor.
ERK1/2 signaling also seems to be important for the role of oxytocin
in its ability to support the repair and maintenance of skeletal muscles.
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Studies on mice have indicated that a declining oxytocin function with
age may contribute to sarcopenia and the decreased capacity for mus-
cles to repair in old individuals [30]. Muscles in old mice are char-
acterized by a blunted tendency of satellite cells to differentiate into
muscle cells, but this decline can be counteracted by oxytocin. Ac-
cordingly, oxytocin treatment of old mice was found to restore muscles
repairment after an injury to a level similar to that of the young mice. In
contrast, muscle repairment in the young mice was impaired by
blocking the effect of oxytocin. Furthermore, in the same article, leg
muscle atrophy was observed to be more pronounced in old oxytocin
knockout mice compared to wild-type mice. The involvement of the
ERK1/2 pathway in the activation by oxytocin of satellite cells was
supported by the observation that the proliferative effect of oxytocin on
satellite cells collected from damaged muscles tissue was abolished
when an inhibitor of this pathway was applied.
Oxytocin may play a very important role in the renewal and pro-
tection of various types of mucosal linings and dermal tissue. A study in
rats has demonstrated that intraperitoneally administered oxytocin
ameliorated injuries on ileal mucosa induced chemically or by radiation
[31]. The protective effect of oxytocin was eliminated by co-adminis-
tration with a PGE-2 inhibitor. In the same article, oxytocin was re-
ported to trigger pulsatile PGE-2 release in small intestine dissected
from rats. Furthermore, a proliferative impact of oxytocin on the gut
mucosa is supported by findings of shortened villi and crypts in oxy-
tocin receptor knockout mice accompanied by an increased suscept-
ibility to colitis inducing agents [32]. In humans, topical treatment with
oxytocin gels has been found to ameliorate postmenopausal atrophy of
the vaginal mucosa [33–35] which may be explained by an improved
maturation and proliferation of the epithelial cells [36]. An accelerated
healing of inflicted skin wounds obtained by probiotic treatment with
Lactobacillus Reuteri has been reported from mouse and human experi-
ments [37]. L Reuteri supplementation to the drinking water was found
to upregulate oxytocin activity in mice and the healing promoting effect
of the bacteria was abolished in an oxytocin knock-out model [38].
Oxytocin has also been suggested to be involved in a faster wound
healing process found associated with a positive marital behavior [39].
Oxytocin mediated mechanisms in the brain which supports peripheral
tissue survival may exist as indicated by an experiment where the
survival of surgically constructed dorsal musculocutaneous flaps was
improved in rats by intracerebroventricularly injections of oxytocin
[40]. The authors proposed that IGF1 and other growth factors could be
involved.
Oxytocin may also protect pancreatic islets cells during metabolic
and inflammatory stress which may be important to delay the devel-
opment of type-2 diabetes. In this regard, the ERK1/2 signaling
pathway also appears to be pivotal. This was indicated by a study on
oxytocin receptor knockout mice (OTR-/-) being fed a high fat diet [41].
The pancreas of the OTR-/- mice did not demonstrate a pathological
phenotype after a normal dietary regimen and their glucose tolerance
was similar to what was observed in the wild-type mice. However,
glucose tolerance was more impaired in the OTR-/- mice after a high fat
diet accompanied by a reduced insulin response compared to the wild
type mice. Furthermore, islets samples showed a greater number of
dead and apoptotic cells in the OTR-/- mice than in the wild-type mice
after the high fat diet. The further finding that active phosphorylated
form of ERK1/2 was less abundant in the islets cells of the OTR-/- mice
compared to the wild-type mice after a high fat diet suggests that ERK1/
2 signaling is involved in the protective effect on islets cells of intrinsic
oxytocin. Possible protective and maintenance mechanisms mediated
by ERK signaling are outlined in Fig. 1.
Oxytocin protects against inflammatory stress and degeneration – evidence
from laboratory experiments
A number of animal experiments have documented a significant
protective potential of oxytocin both against inflammatory crises and
different slowly progressing degenerative processes. This is the case for
studies on isolated organs as well as living animals. The effects of
oxytocin may be conveyed from the hypothalamus both by humoral
routes and by the autonomous nervous system. Furthermore, different
other organs are capable to synthesize oxytocin including the heart
[42], gut [43], skin (keratinocytes) [44], prostatic glands [45] and
gonads [46].
An acute direct cardioprotective effect of oxytocin has been de-
monstrated in different investigations. In ischemia-reperfusion (IR)-
studies on rats hearts a decreased infarct size, a decline in arrhythmic
incidences and a better hemodynamic control was found when oxytocin
was administered intraperitoneally prior to the ischemia [15,16]. The
involvement of NO in a cascade which promotes antioxidative functions
may be important for the protective effect of oxytocin as it could be
abolished by a nitric oxide synthase inhibitor. An IR study on the kid-
neys has accordingly demonstrated an ability of oxytocin to protect
renal function, to reduce the oxidative stress (less lipid peroxidation)
and to attenuate the inflammatory response [47]. Oxytocin has also
been reported to mitigate the damages with IR in the liver likewise
accompanied by dampened inflammatory reaction [48]. Furthermore,
subcutaneous administration of oxytocin resulted in a reduction in the
blood level of the inflammatory cytokine TNF-α and markers of oxi-
dative stress in the stomach during extensive thermal skin trauma in
rats [49]. The latter study indicates that oxytocin may have a relieving
effect on systemic traumatic conditions.
The mechanisms and intra-cellular pathways by which oxytocin
may protect the vascular system has been discussed in a recent ex-
haustive review [50] and the present article will therefore mostly be
restricted to focus on particular biological, behavioral and treatment
issues. Inflammation accompanied by oxidative stress of the vascular
wall is well established in the etiology of atherosclerosis and research to
approach the disease by anti-inflammatory drugs is in its infancy [51].
Increased adhesion to the endothelial cells of activated macrophages
promotes the transfer of oxidized LDL-particles into the arterial wall.
This is suggested as a major inflammatory mechanism to accelerate
plaque formation.
Long term antioxidative and anti-inflammatory effects of oxytocin
may therefore have a delaying impact on the progress of cardio-vas-
cular diseases. Several studies support an antiatherogenic potential of
oxytocin. I heritable hyperlipidemic rabbits, the development of aortic
atherosclerotic lesions was reduced when the blood level of oxytocin
was constantly elevated via infusion pumps [52]. In this study, the
oxytocin infusion had no significant effects on blood lipids and cortisol
level. However, C-reactive protein was lower indicating a systemic anti-
inflammatory effect of oxytocin. Similar results with oxytocin infusion
have been reported from a study on hyperlipidemic ApoE−/− mice,
where the antiatherogenic effect of oxytocin was accompanied by de-
crease in the secretion of the proinflammatory cytokine IL-6 from epi-
didymal fat tissue [53]. However, local anti-inflammatory effects on the
arterial wall may add to the systemic effects of oxytocin. Thus, a di-
minished IL-6 secretion and NADPH oxidase dependent superoxide
production was seen in incubated endothelial cells, vascular muscle
cells and macrophages when oxytocin was added to the medium in
physiological concentration [54]. Oxytocin has also been reported to
mitigate the vascular damages caused by general oxidative stress im-
posed by adding methionine to the chow in rats. The methionine sup-
plementation led to thickening of the aortic wall and elevated levels of
NF-κB protein in the vascular tissue, but daily intraperitoneal admin-
istration of oxytocin was found to counteract these effects [55].
Dysfunctional mitochondria may be crucial in the pathogenesis of
atherosclerosis. Most of the mitochondrial proteins are encoded for in
the nucleus but some of the genes which code for proteins that con-
stitutes the respiratory complexes are still situated in the mitochondria
where they are more vulnerable to mutations. It is hypothesized that
such mutations accumulate with increasing age of the organism re-
sulting in the impairment of the electron transfer through the
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complexes. This would cause an increased ROS production due to su-
peroxide formation by oxygen being reduced by escaped electrons [56].
The ROS formed could further damage the mitochondrial DNA leading
to the constitution of a vicious cycle. If the defective mitochondria are
not eliminated, they would increase the oxidative burden of the cell
which, in turn, also may augment the inflammatory activity. The idea,
that dysfunctional mitochondria may play a role in atherosclerotic
plaque formation is supported by findings of abnormal mitochondrial
morphology and greater variation in mitochondrial genes in samples
taken from atherosclerotic plaques compared to samples from the
normal intima [57]. The importance of ROS derived from the mi-
tochondria in vascular aging processes is supported by a study with
transgenic mice expressing a human catalase gene in their mitochondria
[58]. The manipulation resulted in a 50x higher expression of catalase
in their heart mitochondria compared to the wildtype. Catalase is an
enzyme which reduces the ROS activity by converting hydrogen per-
oxide to oxygen and water. Less atherosclerosis of the cardiac arteries
was seen in the transgenic mice at the age of about 20 months. Fur-
thermore, the transgenic mice lived significantly longer (about 20%)
and pathology examinations of their heart showed fewer sign of myo-
pathy.
One study supports that oxytocin may alleviate the consequences of
mitochondria being stressed by long-term environmental factors. Mice
which have been stressed as pups by separation from their mother
during a 3-hour period each day demonstrated depressive-like behavior
later in life accompanied by an elevated inflammatory state and oxi-
dative stress in the hippocampus [59]. Furthermore, ROS production
was increased in mitochondria isolated from hippocampus. If oxytocin
was injected intracerebroventricularly prior to the behavioral tests the
stressed mice performed better in the tests and showed less hippo-
campal inflammation with an improved mitochondrial function.
A direct anti-inflammatory effect of oxytocin has been supported by
several experiments both on local and systemic levels. Subcutaneous
injection of oxytocin has been reported to ameliorate the injuries
caused by intracolonic administration of acetic acid. This was
accompanied by a blunted serum response of TNF-α [60]. In another
study, the inflammatory response to injection of carrageenan under the
skin was attenuated by coadministration of oxytocin [61]. The presence
of an anti-inflammatory role of oxytocin in the skin has also been
supported by in-vitro experiments with human skin cells [62]. In that
study, cultured keratinocytes had an increased secretion of pro-in-
flammatory cytokines if their oxytocin receptor had been knocked
down by a small interfering RNA technique. In a study on healthy men,
an attenuated systemic inflammatory response (including fever) to a
bolus infusion of bacterial endotoxin has been observed with in-
travenous administration of oxytocin [63]. In an in-vitro test, incubation
with oxytocin of macrophages which were sampled from rat bone
marrow and differentiated caused them to secrete less TNF-α [64].
Accordingly, in the same publication, adipose tissue of dietary obese rat
was reported to have a reduced TNF-α expression when the animals had
been treated with oxytocin. Adipose tissue secretion of another im-
portant proinflammatory cytokine, IL-6, has also been found to be di-
minished by oxytocin treatment [53]. Possible anti-inflammatory me-
chanism of oxytocin is outlined in Fig. 2.
Inflammation and adipocyte regulation in the metabolic syndrome
A dampening of the general inflammatory status of the body may be
an important preventive measure against cardio-vascular diseases. This
may particularly apply to elderly or overweight individuals where the
systemic inflammatory activity is more pronounced. Apart from the
direct damaging effect on the arterial wall, inflammatory stress may
also exert an impact on pancreas, muscles, liver and brain which may
be detrimental to the blood vessel by secondary avenues. Pro-in-
flammatory cytokines produced in the adipose tissue may contribute
with an important share to the general inflammatory level. Visceral
obesity as a risk factor for atherosclerosis has to a large extend been
attributed to the inflammatory activity of the adipose tissue itself [65].
This can be explained both by a direct promoting effect on athero-
sclerotic lesions and by a detrimental impact on the insulin function.
Fig. 1. General effects of oxytocin mediated by ERK signaling.
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However old age, per se, is associated with a reduced insulin sensitivity
as demonstrated in a study where young and elderly men with similar
body composition were compared [66]. A decreased glucose tolerance
in the elderly men was accompanied by a greater fat accumulation in
the skeletal muscles and liver. Furthermore, they showed a reduced in
vivo oxidation and phosphorylation activity in the skeletal muscles
indicating an impaired mitochondrial function. Accordingly, decline in
respiratory rate and capacity with age has been demonstrated in muscle
homogenates in an early human study [67]. In addition to a compro-
mised capacity for glucose uptake by the skeletal muscles, an eroded
mitochondrial function may contribute to the general age-associated
enhancement of the inflammatory activity. Moreover, an increased se-
cretion with age of proinflammatory cytokines by adipose tissue may be
an important factor to enhance the systemic inflammatory level. Visc-
eral adipose tissue sampled from old rats have been shown to express
more TNF-α, IL-6, IL-1β but less PPAR-γ compared to what was found in
young rats [68]. PPAR-γ has been found to be an important attenuating
factor for the immune response in adipose tissue but also in other or-
gans including the brain [69].
Apart from being a transcription factor which counteracts the pro-
duction of proinflammatory cytokines, PPAR-γ is a key promoter of
adipocyte differentiation and proliferation [70]. A reduced PPAR-γ
activity with age may therefore be involved in the attenuated capacity
of preadipocytes and adipocytes to differentiate, proliferate and pre-
serve their role as a lipid storing entity [71]. This could be a crucial part
of the age-related pathology leading to insulin resistance and cardio-
vascular disease. An enhanced gene expression of PPAR-γ in visceral
adipose tissue has been observed in rats subcutaneously infused with
oxytocin during a 2-week period which resulted in plasma concentra-
tions of approximately 6x the basal level [72]. Accordingly, the size of
the epididymal adipocytes was reduced by oxytocin indicating a pro-
liferative effect of the peptide. Large visceral adipocytes reflecting a
poor proliferative activity have been found to be a strong marker of an
atherogenic blood lipid profile, insulin resistance and liver damages in
Fig. 2. Anti-inflammatory mechanisms of oxytocin.
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obese humans [73]. Furthermore, the increased PPAR-γ expression in
the oxytocin treated rats was accompanied by an elevated expression of
adiponectin, which is an adipokine with anti-inflammatory and anti-
atherogenic properties [74].
An adipogenic effect of oxytocin appears to be contradictory to its
role as a nutrient mobilizing hormone. However, a possible promotion
of fat storage by the upregulation of PPAR-γ may be counteracted by a
contemporarily promotion of the PPAR-α activity. Thus, in-
tracerebroventricular infusion of oxytocin in rats leading to increased
hypothalamic oxytocin gene expression and elevated plasma oxytocin
concentrations has been reported to upregulate the synthesis of oleoy-
lethanolamide in epididymal adipose tissue [75]. Oleoylethanolamide
is an activating ligand for PPAR-α. PPAR-α is a transcription factor for
several enzymes involved in uptake and oxidation of fat including li-
poprotein lipase, hormone sensitive lipase, and acyl-CoA oxidase. Ac-
cordingly, an augmented gene expression of these enzymes by oxytocin
was seen in that study. The central oxytocin infusion also resulted in a
lower plasma triglyceride concentration whereas that of glycerol was
increased indicating an enhanced blood lipid uptake and adipose tissue
lipolytic activity, respectively. In relation to lipoprotein lipase expres-
sion it might have been interesting if other organs had been examined
including liver, skeletal muscles and heart where the expression of
PPAR-α is more prominent [76].
The overall impact of oxytocin on fat metabolism therefore appears
to be a promotion of the utilization of fat as a fuel by the enhancement
of enzyme activity involved in fat oxidation. Such an effect seems
plausible considering that nursing may increase the likelihood for the
mother to face a state of negative energy balance. Observations of a
reduced respiratory quotient after treatment with oxytocin both in a
pair-feeding experiment with rats [75] and acutely in fasting humans
[77] support this notion. Furthermore, the concomitant increase in
triglyceride clearance and lipolysis in adipose tissue induced by oxy-
tocin has been suggested to accelerate futile cycle thermogenesis [78].
A thermogenic effect of oxytocin has been confirmed in rats by a
blunted weight gain during high-fat feeding compared to pair-feed
control rats [75]. An important role of oxytocin in thermoregulation has
been demonstrated in oxytocin knock-out mice showing an impaired
capacity to defend their body temperature during cold exposure [79].
The thermogenic potential of oxytocin may have evolved by the need to
protect the pups from hypothermia. However, at the same time, an
increased energy expenditure may contribute to the weight loss ob-
served in humans [80] and rhesus monkeys [81] when treated with
oxytocin for several weeks.
The improving effect of oxytocin on skeletal muscle insulin sensitivity may
involve activation of AMPK
Kinase activation of AMPK in the skeletal muscles has been pro-
posed as an important factor for substrate mobilization during stren-
uous and endurance exercise. In this context, both contraction- and
insulin dependent glucose uptake may involve the activation of AMPK
[82]. Oxytocin may support this system during metabolic challenges.
An increased glucose uptake has been reported to be induced by oxy-
tocin in C2C12 myoblast [6] and cardiomyocytes from newborn rats
[83]. In both cases, this effect was abolished by blocking the AMPK
pathway. The effect of oxytocin on glucose uptake was potentiated
when metabolic stress was imposed on the cardiomyocytes suggesting a
protective capacity of oxytocin e.g. during hypoxia.
In addition, AMPK also plays a role in the mobilization of fat as a
fuel. Malonyl-CoA synthesized by acetyl-CoA carboxylase is a gate-
keeper of fatty acid entering of mitochondria for oxidation. Activated
AMPK enhances fat oxidation by inhibiting acetyl-CoA carboxylase.
Fig. 3. Effects of circulatory oxytocin on cardiovascular risk profile.
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Consequently, a compromised AMPK function may lead to a reduced
insulin sensitivity of the skeletal muscles [84] with myocytes showing
excessive lipid accumulation as a phenotypic marker of a poor fat
oxidation capacity and insulin resistance. A deteriorated insulin sensi-
tivity in gastrocnemius muscles of old compared to young rats has been
found to be accompanied by less AMPK on its active phosphorylated
form [85]. One-week treatment with the specific AMPK activator
AICAR improved basal and insulin stimulated muscular glucose uptake
in the old rats. Furthermore, the AICAR treatment also resulted in an
alleviation of blunted expression of the insulin dependent glucose
transporter GLUT4. Pharmacological activators of AMPK including
metformin are widely used in the treatment of type-2 diabetes [86]. It is
therefore feasible that a promoting impact of oxytocin on AMPK also
directly exerts an insulin sensitizing effect on the skeletal muscles. In
addition, the counteracting impact of oxytocin on sarcopenia [30]
could probably be an important factor for the maintenance of skeletal
muscles as an insulin responsive glucose clearing organ during aging.
Possible routes for oxytocin to improve cardiovascular risk profile are
outlined in Fig. 3.
Oxytocin protects pancreas and autonomous nerve function against age-
associated deteriorations
The general anti-inflammatory effect of oxytocin which also en-
compasses a blunted response of pancreatic beta cells to metabolic
stress [41] may have a preventive role against an impaired insulin
function and type-2 diabetes late in life. Inappropriate pancreatic in-
flammation may lead to death of the beta-cells [41]. Insulin secretion
has been found to be less affected by chemical oxidative stress after
oxytocin administration in rats [80]. Pancreatic effects may therefore
partly explain that an impaired glucose tolerance in old compared to
young rats was improved by intraperitoneal injection of oxytocin
during a 5-days period whereas no such effect was observed in the
young rats [87]. In addition, the elevated levels of serum triglyceride
and proinflammatory cytokines in the old rats were reduced by the
oxytocin treatment to a level similar to what was seen in the young.
Furthermore, following oxytocin treatment, homogenates of soleus
muscle and epididymal fat from the old rats showed less inflammatory
activity and oxidative stress assessed by malondialdehyde content.
The role of brain in the etiology of the metabolic syndrome and
atherosclerosis cannot be overestimated. In this regard, a hyperactive
sympathetic nervous system as a crucial factor has been well estab-
lished for decades [88]. Sympathetic overactivity impairs endothelial
function [89] which may lead to chronic hypertension and an increased
level of vascular inflammation. Furthermore, it has also been reported
to be statistically associated with dyslipidemia [90]. The para-
ventricular nucleus of the hypothalamus (PVN) appears to be an im-
portant part of the regulatory system governing the sympathetic tone in
relation to blood pressure control [91]. Several studies support the idea
that an elevated ROS production in the pre-autonomic PVN neurons
induced by hyperactivity of their angiotensinergic innervation may
result in a persistent augmented sympathetic tone. This may, in turn,
promote the pathogenesis of the metabolic syndrome [92]. This idea is
in line with the more general hypothesis that neuroinflammation par-
ticularly in the hypothalamus plays a pivotal role in the etiology of this
condition [93].
It may be even more intriguing that hypothalamus beyond being the
head quarter for body homeostasis also - by internal inflammatory
processes - may represent the main regulator of general aging. In ex-
periments with mice the inflammatory activity locally in the medio-
basal hypothalamus was manipulated by up- or downregulation of NF-
κB activity using an injected viral vector to express transcripts with
promoting, respectively inhibiting effects on NF-κB [94]. Mice with
downregulated hypothalamic NF-κB function had an increased lifespan
and maintained their cognitive capacity, muscular size and strength,
bone mass and dermal thickness better with age compared to the
control mice. The opposite was the case for the NF-κB upregulated
mice. In the same study, hypothalamic NF-κB activity was found gra-
dually to increase with age accompanied by on increasing TNF-α pro-
duction by the microglia cells in non-manipulated mice. The life ex-
tending effects of the downregulated hypothalamic inflammation was
suggested to involve a protection of the gonadotropin-releasing hor-
mone (GnRH) production which, in turn, may support restorative
functions in the brain. Interestingly, GnRH might therefore be a sig-
naling molecule which in parallel to oxytocin links reproduction with
longevity.
An attenuating effect of oxytocin on the neuroinflammatory re-
sponse to lipopolysaccharide (LPS) has been demonstrated. This was
done both with isolated microglia cells pretreated with oxytocin and in
frontal cortex tissue dissected from mice given oxytocin intranasally
where LPS had been injected peritoneally [95]. Oxytocin may have a
great potential to unfold its antioxidative and anti-inflammatory
properties in the brain. At its production sites in paraventricular- and
supraoptic nuclei oxytocinergic neurons are known to release oxytocin
from their dendrites where it may travel through the intracellular fluid
and reach neighboring parts of the hypothalamus [96]. Furthermore,
the network of oxytocinergic projections to other areas of the brain [97]
may be speculated also to have an anti-inflammatory capability.
Apart from counteracting neuroinflammation another cerebral role
of oxytocin may be to influence the classic regulation of the autonomic
nervous system. Oxytocinergic nerves project from PVN to different
nuclei in the brainstem including the dorsal vagal complex (DVC) [98]
which gives rise to vagal efferents innervating the thoracic and
splanchnic areas including heart and pancreas. DVC also plays a crucial
role in the brains control of glucose homeostasis [99] and blood pres-
sure. Surprisingly, oxytocinergic innervation of DVC appears to be an
integrated part in the baroreflex control of blood pressure [100]. Fur-
thermore, oxytocin projection to the brainstem may participate in the
general setting of the parasympathetic tone as demonstrated in ex-
periments where rats were exposed to chronic intermittent hypoxia-
hypercapnia (CIH/H) as a surrogate for obstructive sleep apnea [98].
Similar to what is seen in humans with sleep apnea the rats developed
hypertension. This was accompanied with a reduced oxytocinergic
outflow to the DVC. Furthermore, blood pressure was normalized
during CIH/H if the decline in oxytocin release in the DVC was abol-
ished by optogenetic activation of the PVN oxytocinergic neurons.
Maintaining a high oxytocinergic activity of the PVN may therefore
alleviate damages of the heart inflicted by chronic hypertension. In a rat
study, left ventricular overload was established by surgical trans-as-
cending aortic constriction [101]. After 8 weeks, the operated animals
had developed fibrosis in their left ventricular walls and a reduced basal
and stimulated contractility compared to the control group. These
cardiac deteriorations could be mitigated by a chronic activation of the
PVN oxytocinergic neurons which resulted in an elevated vagal sti-
mulation of the heart.
In addition to the capacity to enhance the parasympathetic activity,
oxytocin may also dampen the sympathetic tone by increasing the
production of α2-adrenoceptors in different parts of the brain [102].
α2-adrenoceptors acts inhibitory and an upregulation by oxytocin of
these receptors particularly in locus coeruleus [103] may make the
brain less sensitive to stressful stimuli. As locus coeruleus is the major
site for cerebral noradrenergic output this could mean that its down-
regulation may lead to a reduced sympathetic responsiveness but, in
fact, also an attenuated arousal of the hypothalamic–pituitary–adrenal
(HPA) axis. An upregulation of the α2-adrenoceptors may therefore
have a long-term protective effect against the detrimental effects of
mental and physiological stress on blood pressure, metabolism and
immune function. Treatment of rats with oxytocin subcutaneously or
intracerebroventricularly during a 5-days period has been reported to
have a blood pressure lowering effect which lasted more than week
after the treatment was ceased [104]. Mechanisms of an increased
hypothalamic oxytocinergic activity on cardiovascular risk profile are
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outlined in Fig. 4.
Interactions with ANP
A stimulating effect of circulating oxytocin on cardiac release of
atrial natriuretic peptide (ANP) has also been suggested to be involved
in blood pressure regulation – particularly in relation to blood volume
[105]. ANP has also been demonstrated to induce human white adi-
pocytes to acquire brown adipocyte features including the expression of
uncoupling protein 1 accompanied by an increased mitochondrial
biogenesis and respiratory rate [106]. An enhanced ANP release may
therefore contribute to the increased UCP1 expression in fat tissue
samples and moderately reduced fat gain found in db/db mice when
treated with oxytocin [107]. The so-called beige adipocytes residing
within the white adipose tissue have been proposed to support energy
and glucose homeostasis also in humans and to be a possible target for
obesity treatment [108]. In general, the ability of oxytocin to stimulate
ANP secretion may therefore make this peptide oxytocin’s most im-
portant cardioprotective partner as ANP exhibits several properties
counteracting cardio-vascular risk factors. Its different impacts can be
exerted both by humoral routes and locally in the heart [109]. Oxytocin
in the blood as well as oxytocin synthesized locally in the heart may
delay atherosclerotic and cardiomyopathic processes otherwise ac-
celerated by age, obesity and diabetes. This can be done by oxytocin
alone or assisted by ANP [110].
The hypotesis evaluated: what does human studies indicate?
Experimental studies
Most of our knowledge about oxytocin is based on experiments with
rodents which may differ to some degree from humans in their re-
sponsiveness of several organ systems to the peptide. Human research
on oxytocin has mostly been focused on potential treatment effects for
social disorders with the peptide administered nasally. In this context
several different improvements had been reported from the labs but the
applicability of oxytocin in the clinic for example to alleviate social
deficits in autistic individuals calls for a lot of further field studies
[111]. Nevertheless, these studies document that at least some brain
areas can be reached with a therapeutic effect by exogenous oxytocin
also in humans. However, very high doses of oxytocin may be required
to achieve the central effects due to the poor nasal penetrance of the
peptide. This would probably result in leakage to the general circula-
tion in amounts having additional peripheral impacts [112]. This fact
should also be considered in the interpretation of the few human studies
addressing biological effects of oxytocin given by the nasal route.
Both central and peripheral effects of oxytocin might therefore have
contributed to a reduced postprandial snack intake and a blunted glu-
cose response to the breakfast after nasally administered oxytocin in
men [113]. However, a reduction in ACTH and cortisol after oxytocin
observed in the same study is rather likely only to be caused by central
effects. In another study on men, indirect calorimetry revealed an in-
crease in fasting fat oxidation and a correspondingly decrease in car-
bohydrate oxidation 30 min after nasally administered oxytocin [77]
suggesting promotion of fat utilization in line with what is found in
rodents [75]. The anorectic effect observed acutely with nasal oxytocin
administration [77,113] seems to persist for weeks as a marked weight
loss was reported in overweight subjects after 8 weeks treatment with
self-administration of a nasal oxytocin spray prior to the three main
meals and before bed [80]. A decline in total cholesterol and low-
density lipoprotein following the 8 weeks oxytocin treatment was also
seen. A capacity of oxytocin treatment to improve blood lipid in human
is supported by an early study in young women where an intravenous
bolus injection led to a decline in blood triglycerides. This was ac-
companied by increasing blood levels of non-esterified fatty acids and
decreasing blood glucose [114].
Endogenous oxytocin may be mobilized with different positive ef-
fects by a variety of behaviors. An acute enforcement of the whole body
antioxidative defense by breastfeeding is indicated by observations of
an attenuated oxidative stress response of the mother to cesarean sec-
tion if the infant was put to the breast immediately after the operation.
Furthermore, post-surgical total oxidant status in serum was negatively
correlated with the serum oxytocin level [115]. In addition, a reduced
activity and responsiveness of the hypothalamic–pituitary–adrenal
(HPA) axis during breastfeeding has been reported by several studies
[116] supporting the acute anti-stress effect of lactation. Interestingly,
both breastfeeding and mechanical breast stimulation in non-lactating
women has been reported to elicit an augmented plasma oxytocin ac-
companied by a decline in plasma ACTH and cortisol [117]. Repeated
burst of oxytocin induced by recurrent episodes of lactation might po-
tentiate the capacity for releasing oxytocin and the sensitivity to the
peptide by the targeted cells. This potentiation may be hypothesized to
Fig. 4. Mechanisms of an increased hypothalamic oxytocinergic activity on cardiovascular risk profile.
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show a resilience which enables it to exert a cardioprotective impact for
decades after the nursing period.
Apart from breastfeeding, sexual activities may also elicit robust
bursts of oxytocin regularly. More than 4 times higher plasma levels of
oxytocin have been reported in men at ejaculation compared to baseline
in one study [118]. Plasma oxytocin concentrations had been reported
to increase gradually during masturbation in both genders until it
peaked at orgasm in men. In women, it continued to rise if a second
orgasm could be achieved. Both baseline levels and the increase with
masturbation was higher in women compared to men [119]. In another
masturbation study, the relative increase in plasma oxytocin from
baseline to orgasm was found to be positively correlated to the or-
gasmic pelvic muscle contraction both in men and women. In the
multiorgasmic women, the relative oxytocin increase was also corre-
lated to the subjective rating of the intensity of the orgasms [120]. The
release of oxytocin during sex may be closely linked to the pleasure
sensation as naloxone has been found to inhibit the rise in plasma
oxytocin accompanied by a blunted feeling of pleasure during orgasm,
despite that the rise in heart rate and blood pressure at orgasm was
unaffected by naloxone [121]. This is in line with the observation of a
lacking response of serum oxytocin to coitus in anorgasmic women
[122]. It should be emphasized that elevations in the blood level of
oxytocin may reflect a relatively much more pronounced increment of
the oxytocinergic activity and impact in the brain.
Factors not directly involved in reproduction may also affect oxy-
tocin activity. Oxytocin has been suggested to play an important role in
the tranquilizing effect of non-sexual but pleasant tactile stimulation
[123]. In rat experiments gentle stroking of their back has been seen to
evoke an increased activity in oxytocinergic neurons in the hypotha-
lamus [124] and massage-like stroking applied regularly was found to
result in sustained higher levels of oxytocin in blood and periaquaductal
grey matter [125]. In humans manually performed upper back massage
has been reported to induce a modest enhancement in plasma oxytocin
[126] and this method is recommended to reinforce breast feeding in
some Asian and Middle eastern cultures [127]. In men, both manually
and mechanically applied foot massage has been demonstrated to in-
crease plasma oxytocin concentration [128]. However, in this study, the
manual massage induced a more pronounced response and was claimed
to be more pleasurable.
The sensation of love or other kind of affiliation may also evoke an
oxytocin response as demonstrated during positive interactions be-
tween human and pets [129,130]. Finally, strenuous exercise may in-
crease plasma concentration of oxytocin but studies in humans are in-
consistent [131].
The epidemiological support of a cardioprotective effect of oxytocin
Cross-sectional studies associating oxytocin blood levels or other
proxies of oxytocin activity to cardiac risk factors can not disclose
causal relationships. Furthermore, research on genetic polymorphisms
of the oxytocin receptor seems to be reserved for psychiatry whereas
reports from prospective studies with direct assessment of baseline
oxytocin parameters appears to be totally conspicuous by their absence
but such investigations may be ongoing. What is left to provide any
evidence in humans for the health protective potential of oxytocin are
studies where activities known to elicit a robust oxytocin response are
associated with different risk factors. In this case, the research per-
taining to breastfeeding may be the most convincing.
Several retrospective studies indicate that breast feeding provides a
long-lasting preventive effect against the development of cardio-vas-
cular diseases. Postmenopausal women with a median age of 63 years
who reported a lifetime history of more than 12 months of lactation had
a lower prevalence of hypertension, diabetes, hyperlipidemia and car-
diovascular disease even after adjusting for number of child births,
present BMI, and sociodemographic and lifestyle variables compared to
women who never had breastfed [132]. An independent inverse dose-
response relationship between the total duration of their lactation his-
tory and the risk of presenting 3 or more characteristics of the meta-
bolic syndrome were seen in women at their menopausal transition
phase [133]. A risk reduction by lactation in the development of hy-
pertension and cardio-vascular disease at 7 years post-partum follow-up
has been detected both in groups of mothers who were normal weight/
underweight and those who were overweight at the time of pregnancy
[134]. Middle-aged mothers who had reported to having breast-fed
each of their children for at least 3 mounts were found to be less likely
to display coronary artery and aortic calcifications and showed less
carotid plaque formations compered to mothers who never had
breastfed [135]. These observations points to a protective effect of
lactation against cardio-vascular diseases which last for several years.
The involvement of epigenetic mechanisms could be hypothesized as
the oxytocin system might be a target for epigenetic modulations.
However, the involvement of other signal molecules associated with
breastfeeding including prolactin cannot be excluded.
The possible protective impact of regular sexual engagements on the
development of cardiovascular disease is less elucidated compared to
that of breastfeeding. However, there are a few longitudinal studies
which indicate a cardioprotective effect of sex. In a 25 year follow up
study on volunteers examined at a medium age of 70 years, past en-
joyment of intercourse in women and frequency of intercourse in men
was found to be a predictor of longevity in a model, where possible
confounding factors such as socio-economic status, tobacco use, health-
and physical function ratings and satisfaction parameters were included
[136]. In an investigation on middle-aged men, frequency of orgasms
was negatively associated with all-cause mortality and tended to be
negatively associated with coronary heart disease mortality at 10 years
follow up also when data were adjusted for health- and socio-economic
factors [137].
However, the causality of the observed associations between sexual
parameters and cardiovascular disease are difficult to clarify. It is well
established that erectile dysfunction often precedes coronary heart
problems [138] and may be a marker of an impaired endothelial
function. Concurrently, erectile dysfunction may reduce sexual activity.
However, mechanisms related to oxytocin may also contribute to these
findings. Positive effects of oxytocin release triggered by sexual plea-
sure may be similar to those hypothesized with breast feeding. One
cross-sectional study on predicting factors for telomere length in var-
ious blood cells in young to middle aged women provides very inter-
esting finding in this context. Different indices of health, stress, beha-
vior and partner relationship quality were tested. Amongst these
parameters recent sexual intimacy was the only variable which showed
a highly significant association with telomere length in a multivariate
correlation analysis [139]. High levels of oxytocin may have a de-
fending effect against telomere truncation as suggested by a study
where the protecting effect of social housing against telomere erosion in
female rats could be abolished by the treatment with an oxytocin an-
tagonist [140]. Telomeres appears to be particularly vulnerable to
oxidative degradation [141] and a possible effect of oxytocin counter-
acting telomere attrition may be mediated by antioxidative effects.
The engagement in romantic relationships may rise the baseline
plasma oxytocin level. Higher plasma levels of oxytocin have been
detected in subjects of both genders being involved in courtships
compared to singles [142]. Amongst couples, plasma oxytocin was
found to be positively correlated with indices of mutual attachment
[142] or experienced support [143] between the partners. In addition,
affiliations of non-sexual, non-familial nature also appears to enhance
the hormonal oxytocin level [144]. A cardioprotective impact of emo-
tional bonds appears to be well established and supported by findings of
an association between social isolation and risk of developing cardio-
vascular disease [145]. Pet ownership may relieve the detrimental ef-
fects of social isolation in some individuals by having a beneficial im-
pact on risk factors including blood pressure, autonomic function and
blood lipids [146]. In particular, dog ownership is associated with a
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pronounced risk reduction in cardiovascular mortality [147]. The ex-
tent to which oxytocin is involved in the cardioprotective impact of
social bonds in humans is difficult to clarify for ethical reasons.
Pharmacological aspects
Nonpharmacological approaches, including sexual pleasure and
romantic relationships, may be insufficient fully to exploit the cardio-
protective potential of oxytocin particularly during the later decades of
life where the oxytocin function may have declined. In particular, it has
been indicated that in female rats both the amount of plasma oxytocin
and its receptor may go down with age as a consequence of a dimin-
ished estrogen stimulation [30]. In male rats, there have been reported
a blunted oxytocin response to stress with age [148]. No investigations
appear to have addressed the impact of advanced age on constitutive
levels and responsiveness of oxytocin in humans. However, the in-
creasing incidence of osteoporosis with age particularly in women may
be one indication for an attenuated influence of oxytocin in elderly
people.
Pharmacological treatment with oxytocin or oxytocin analogues
could therefore be a possible preventive remedy in middle age and el-
derly patients exhibiting risk factors for cardiovascular disease.
Traditionally, oxytocin is administered as nasal spray also when aiming
at extracerebral locations such as breasts to promote milk let-down
[149]. Applying this route, elevated plasma levels was observed until
90 min after a single nasal dose in men [150,151] whereas the con-
centration of oxytocin appeared to have a slower kinetic in the cere-
brospinal fluid with increased readings only for the last sample at
minute 75 [151].
Intra-nasal oxytocin administration for several weeks is very well
tolerated in most people and in general, there are only very few reports
of severe side effects with long-term oxytocin treatment including water
intoxication [152]. One case of severe bradyarrhythmia has been re-
ported with oxytocin infusion to induce labor [153] which may have
been caused by excessive vagal stimulation. The impact of oxytocin on
cardiac regulation should always be considered when the peptide is
given to patients with particular heart conditions. Increasing the vagal
tone has in most cases an anti-arrhythmogenic effect, however, frequent
idiopathic slow rate-dependent premature ventricular contractions has
been associated with high levels of parasympathetic activity [154].
Although not harmful, per se, this condition may be bothersome and
reflect an imbalanced autonomic control. In general, it may be im-
portant to include cardiac monitoring regularly during long-term oxy-
tocin treatment in patients displaying an abnormal ECG.
Central effects of oxytocin may be regarded as side effects if oxy-
tocin is applied in the treatment of cardio-vascular disease. Despite that
some cerebral effects may add to a cardioprotective effect the possible
mental consequences of a chronically elevated cerebral level of oxy-
tocin in mentally healthy humans are not sufficient elucidated.
Sublingual or vaginal routes has been addressed as alternative methods
for the administration of oxytocin. A protracted plasma oxytocin con-
centration curve has been reported with sublingual administration.
However, the bioavailability of the dose was very poor and with a
profound variability between subjects [155]. This was also the case in a
study where oxytocin was given as a vaginal gel [156]. Moreover, the
pharmacokinetic of plasma oxytocin is complicated and a two-com-
partment model may be required to give a satisfactory mathematical
model [156]. Early kinetic studies should therefore be repeated with
more accurate methods for the assessment of oxytocin [157] in different
body compartments.
Biologically stable oxytocin analogues may have a prosperous future
in the treatment of obesity and its comorbidities. An enhanced stability
of oxytocin and similar molecules can be achieved when they are
conjugated with lipids. Moreover, apart from the difficulties associated
with the administration and fast degradation of native oxytocin, very
high plasma concentrations of the peptide have been reported to elicit a
transient pressor response in rats [158]. This is probably due to loss of
oxytocin receptor selectivity resulting in actions on the vasopressin
receptors. This might have been a motive for the development of oxy-
tocin analogues with greater receptor selectivity than native oxytocin
by replacing proline at position 7 with glycine. Such a lipid conjugated
analogue was tested in diet induced obese mice [159]. Treatment with
daily intraperitoneal injections of the analogue during a 2-week period
resulted in a weight loss which was more marked than in mice given a
corresponding treatment with native oxytocin. Furthermore, lean body
mass was better conserved in mice treated with the oxytocin analogue.
The high selectivity for the oxytocin receptor of the analogue was re-
flected by an absent acute hypertensive response to the treatment.
However, transient hypertensive effects of native oxytocin may not be
an issue in humans where an acute hypotensive effect rather is the
major concern when high doses of oxytocin is administered. In the fu-
ture, reports addressing possible beneficial effects of oxytocin analo-
gues on inflammatory and tissue maintenance parameters would be
very exciting.
The degradation of oxytocin results in different peptide fragments
which may have their own specific activity. This has been demonstrated
by mouse model showing social deficits corresponding to autism spec-
trum disorders [160]. The synthetic oxytocin receptor agonists TC-OT-
39 and carbetocin failed to exert any prosocial effects whereas some of
the oxytocin fragments did. Furthermore, findings that long-term an-
algesic and hypotensive effects of oxytocin was insensitive to the oxy-
tocin receptor antagonist atociban supports that non-conventional route
of oxytocin signaling possibly involving particular degradation pro-
ducts may exist [161]. Some of the biological effects of native oxytocin
may therefore be absent when applying oxytocin analogues due to a
failed production of metabolites. This could be a matter of concern also
if such analogs are employed for the prevention and treatment of car-
diovascular disease. In general, such unexpected effects specific for
native oxytocin may encourage the research for ways to potentiate the
brains own release of oxytocin beyond what can be achieved by be-
havioral approaches. In this context, microbiotic interventions may turn
out to be very exiting [37].
Consequences and discussion
In this article we have presented some evidence that the oxytocin
system may constitute an important target for the prevention and
possibly treatment of cardiovascular disease. Oxytocin may have sev-
eral avenues at hand to improve cardiovascular health. Atherosclerotic
formations may be counteracted by antioxidative and anti-in-
flammatory effects on the endothelia. Central stress reactions may be
dampened with a reduced activity of the sympathetic nervous system
and HPA axis while the parasympathetic tone is enhanced. By acting on
pancreas and skeletal muscles insulin function can be potentiated. By
stimulating repair and survival mechanisms not at least of the stem cells
the integrity of the myocardium and vascular tissue may be defended.
By promoting restoration of the mitochondria, cellular energy supply is
preserved. This would also be the case for cardiomyocytes sustaining
the contractibility of the heart.
In the future, more knowledge about oxytocin may lead to a con-
ceptual change where a behavior promoting oxytocin release is adopted
as part of a healthy lifestyle. It is needless to say that the establishment
of more and better social bonds is problematic to include in the public
health recommendations. It may be slightly less sensitive to recommend
frequent sexual and tactile pleasures in parallel to regular physical
activity as a health strategy particularly if future research may indicate
effects which are similar to those of breast feeding.
With regard to the pharmaceutical aspects, oxytocin analogues may
be developed which offer a safe treatment regimen and prove a great
efficacy for the prevention of cardiovascular disease (and postponement
of other degenerative maladies). The threshold for prescription of such
agents may become very low and possibly an age above 50 years might
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be a sufficient indication. Meanwhile, indispensable requests prevail for
preclinical and clinical investigations pertaining to the potential of
targeting the oxytocin receptor in the battle against heart problems.
Initially one option may be studies applying nasal administration of
native oxytocin for long term treatment of both men and women who
show risk factors for cardiovascular disease. Would their blood lipid
profile, insulin function, heart rate variability or body fat distribution
be improved?
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